TG Therapeutics: 'Strong Buy' Amid BRIUMVI Expansion Win And Boosted 2026 Outlook

2026-05-28 13:35:11 ET

The last time I spoke about TG Therapeutics ( TGTX ) it was with a Seeking Alpha article entitled " TG Therapeutics: 'Strong Buy' On BRIUMVI's Massive Growth And Possible Expansion ." Regarding this article, I mentioned that the company posted $594 million in 2025 U.S. BRIUMVI sales, which was a 90% year-over-year increase. Along with the fact that it guided higher sales of this relapsing multiple sclerosis [RMS] drug as well to be in a range of between $825 and $850 million. I also mentioned that it was in the process of moving forward with two expansion opportunities as well. One expansion opportunity was in terms of advancing this anti-CD20 monoclonal antibody BRIUMVI as a subcutaneous [SC] self-administered at-home injection for the treatment of RMS....

Read the full article on Seeking Alpha

For further details see: